Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Labels ...

The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...

Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...

Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 ...

We rate McKesson as a 'Strong Buy' with focus on GLP-1 meds, oncology network, and strong Q2 results driving future growth.